Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 74Colorectal Neoplasms 41Central Nervous System Neoplasms 37Colonic Neoplasms 36Rectal Neoplasms 34Glioblastoma 23Carcinoma, Non-Small-Cell Lung 21Gliosarcoma 20Stomach Neoplasms 18Lung Neoplasms 18Pancreatic Neoplasms 16Head and Neck Neoplasms 16Sarcoma 14Ovarian Neoplasms 14Squamous Cell Carcinoma of Head and Neck 13Prostatic Neoplasms 12Neoplasm Metastasis 11Melanoma 11Esophageal Neoplasms 11Carcinoma, Ovarian Epithelial 11Carcinoma, Intraductal, Noninfiltrating 11Astrocytoma 11Fallopian Tube Neoplasms 10Brain Neoplasms 10Uterine Cervical Neoplasms 9Kidney Neoplasms 9Breast Carcinoma In Situ 9Liver Neoplasms 8Breast Neoplasms, Male 8Adenocarcinoma Of Esophagus 8

Interventions

anlotinib 1Chemotherapy, Adjuvant 1Angiogenesis Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stereotactic Body Radiation Therapy × Chemotherapy, Adjuvant × Clear all
NCT05411809 2022-06-09

The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer

Peking University Third Hospital

Phase NA Not yet recruiting
180 enrolled

Stereotactic Body Radiation Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡